Artificial Womb Technology Shows Promise for Improving Survival of Extremely Premature Babies

Globally, an estimated 15 million infants are born preterm each year, representing a massive public health challenge. For the vast majority of these babies, modern medicine provides a reliable safety net. However, for those born at the very edge of viability—typically between 22 and 24 weeks of gestation—the transition to the outside world is abrupt and highly perilous. At this extreme stage of prematurity, their lungs are not yet ready to breathe air, their skin is gelatinous, and their internal organs are profoundly immature. The mortality rate is steep, and those who do survive often face a lifetime of severe health complications.[4]

The current standard of care for these micro-preemies relies heavily on mechanical ventilation and conventional incubators. While undeniably life-saving, this approach is fundamentally unnatural for a fetus that should still be developing in fluid. The mechanical pressure required to force air into underdeveloped lungs can permanently damage fragile tissue, leading to chronic respiratory diseases. Furthermore, the sudden exposure to air and gravity arrests the natural, seamless development that would have occurred in utero. Consequently, the risk of permanent disability in babies born at around 24 weeks remains stubbornly high, hovering at approximately 60 percent despite decades of incremental improvements in neonatal intensive care.

To solve this intractable problem, scientists are developing a radical alternative: Artificial Womb Technology (AWT). Rather than treating these extremely premature infants as small, failing neonates who must be forced to adapt to the outside world, the goal is to treat them as fetuses. By meticulously recreating the fluid-filled, temperature-controlled environment of the maternal womb, researchers hope to provide a physiological bridge. This bridge would allow extremely premature babies to continue their natural development for a few crucial weeks, entirely bypassing the trauma of early air exposure and mechanical life support.[1][5]

The mechanism behind AWT represents a fundamental paradigm shift in neonatal care. Instead of lying on a mattress in a dry incubator, the premature infant is placed inside a sealed, sterile biobag filled with synthetic amniotic fluid that is continuously cycled and maintained at exact maternal body temperature. Crucially, the baby does not use their lungs to breathe air. Instead, oxygen and essential nutrients are delivered—and carbon dioxide is removed—through an external oxygenator that is connected directly to the infant's umbilical cord, perfectly mimicking the gas exchange normally performed by the maternal placenta.[2]

A defining feature of the most advanced AWT systems is that they are entirely pumpless. The fetal heart itself drives the circulation of blood through the low-resistance external circuit, just as it would naturally pump blood to a biological placenta. This elegant design prevents the immense cardiovascular stress that an artificial mechanical pump would impose on an underdeveloped, fragile heart. By relying on the fetus's own hemodynamics, the system maintains a natural equilibrium, allowing the cardiovascular system to mature at its own predetermined biological pace without external mechanical interference.

The evidence supporting the efficacy of this technology has moved rapidly from theoretical conjecture to highly promising empirical data, driven by extensive and rigorous animal models. The Children's Hospital of Philadelphia (CHOP) pioneered the modern era of AWT with their EXTEND (EXtrauterine Environment for Neonatal Development) system. In landmark preclinical studies, the CHOP team successfully supported premature lambs—equivalent in developmental stage to a 23- to 24-week human fetus—for up to four weeks. During this time, the lambs demonstrated normal, healthy growth of the lungs, brain, and other vital organs while submerged in the biobag.[2][3]

A critical, lingering question for the scientific community has been whether gestating in an artificial, engineered environment fundamentally alters delicate brain development. Recent evidence provides strong reassurance on this front. A comprehensive 2025 study led by researchers at Duke University utilized advanced RNA sequencing techniques to analyze brain tissue from animal subjects that had been gestated in the EXTEND model. The goal was to detect any subtle transcriptomic or gene expression changes that might indicate hidden neurodevelopmental harm caused by the artificial environment.[2]

The researchers found that the transcriptomic data from the artificial womb subjects closely matched that of late-preterm subjects that had remained safely in a natural maternal womb. This finding is monumental, as it suggests that the EXTEND system does not introduce additional neurodevelopmental harm or stress to the developing brain. By proving that the artificial environment can foster neurological maturation that mirrors natural gestation, scientists have cleared one of the most significant safety hurdles required before the technology can be considered for human application.[2]

The race to bring this transformative technology to human clinical trials is no longer isolated to a single laboratory; it is now a highly competitive, collaborative global effort. Multiple research hubs are validating their own proprietary systems, each contributing unique engineering solutions to the overarching challenge. In Europe, the fetaLife project—a spin-off consortium involving BCNatal and several major hospitals in Barcelona—has developed a highly functional "liquid incubator" prototype. Backed by substantial institutional funding, the Spanish team is rapidly advancing the technology toward clinical viability.

The European team recently reported groundbreaking results, demonstrating that their liquid incubator system maintained a healthy 21-day survival in an experimental sheep model. Even more importantly, they achieved a postnatal survival of more than 13 months with excellent neurodevelopmental outcomes after the subjects were successfully transitioned out of the liquid incubator and into conventional care. This proves that the critical transition phase—moving the infant from the artificial fluid environment to breathing room air—can be executed safely without compromising long-term health.

In the Netherlands, researchers at the Eindhoven University of Technology are developing the AquaWomb system, bringing a strong focus on industrial design and clinical integration. Their research encompasses not only the physiological life-support mechanics but also the highly delicate transfer procedure required to move the baby from the mother to the fluid-filled incubator. To perfect this unprecedented surgical protocol, the Dutch team is utilizing highly realistic robotic manikins, allowing medical teams to simulate and practice the complex transition in a zero-risk environment before ever touching a human patient.

Meanwhile, in the Asia-Pacific region, the Women and Infants Research Foundation (WIRF) in Australia is advancing its own artificial placenta technology. Their system relies on a remarkably compact, miniaturized gas exchange device—roughly the size of a Rubik's Cube—that connects to the umbilical cord. The Australian team's explicit goal is to give extremely premature babies an extra three to four weeks of protected growth, allowing their lungs and digestive systems to mature before they must face the daunting physiological challenges of eating and breathing independently.

Despite the robust and accelerating preclinical evidence, the transition to first-in-human (FIH) trials remains fraught with profound regulatory and ethical complexities. The United States Food and Drug Administration (FDA) convened a dedicated advisory committee in late 2023 to debate the scientific readiness of systems like EXTEND for human testing. The hearings highlighted the unprecedented nature of the intervention, with regulators demanding airtight protocols to ensure that the first human subjects are not exposed to unacceptable risks during the experimental phase.[3][4]

Regulators, legal scholars, and bioethicists emphasize that AWT creates a completely new stage of human development that defies current legal and medical definitions. The subject inside the biobag is no longer a fetus in utero, yet they are not entirely a breathing neonate in the outside world. Establishing rigorous ethical frameworks for parental informed consent, defining legal viability, and developing reliable methods for monitoring pain perception in this novel, fluid-submerged state are ongoing challenges that must be resolved before trials commence.[3][4]

Furthermore, researchers face significant technical uncertainties that animal models, no matter how advanced, cannot fully resolve. The primary risks for human trials include preventing catastrophic bacterial or fungal infections in the warm, fluid-filled environment over a period of weeks. Additionally, surgeons must ensure that the delicate human umbilical vessels do not spasm, constrict, or clot during the initial transfer process. A failure at the umbilical connection would immediately cut off the infant's only life-support system, leaving virtually no margin for error.[1][5]

To manage public expectations and ethical concerns, scientists universally stress what AWT is not: it is not "complete ectogenesis." The technology is entirely incapable of supporting a fetus from conception, and there is no scientific intent to replace natural pregnancy. It is strictly a life-saving medical bridge designed exclusively for the narrow window of extreme prematurity, typically between 22 and 28 weeks of gestation. Researchers are actively working to dispel science-fiction narratives, framing the device simply as a highly advanced incubator.[3]

The timeline for clinical application is finally coming into sharp focus. While the CHOP team remains in advanced, confidential discussions with the FDA regarding their EXTEND system, European groups are publicly outlining their roadmaps. The fetaLife consortium in Spain is actively targeting 2028 to 2029 for their first human trials, while the AquaWomb team in the Netherlands similarly expects to begin clinical testing within the next five years. The era of the artificial womb is no longer a distant theoretical concept; it is an impending clinical reality.[3]

If these clinical trials are successful, the impact on global public health would be profound and immediate. Projections from researchers suggest that if a baby born at 24 weeks can continue developing in an artificial womb for just one additional month, their survival rate could jump dramatically from 60 percent to 90 percent. This would mirror the much safer outcomes of babies born at 28 weeks, while drastically reducing the incidence of lifelong disabilities, transforming neonatal intensive care from a system of damage control into one of continued natural development.[5]